| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
KLH45 (25 nM, 4 hr) has no cross-reactivity with any of the over 40 identified serine hydrolases, with the exception of ABHD6, and completely inactivates DDHD2 in Neuro2A cells (>95% inhibition)[1]. In DDHD2-expressing cells supplemented with fatty acids, KLH45 (2 μM) enhances LD formation [2].
|
|---|---|
| ln Vivo |
KLH45 (20 mg/kg; given every 12 hours) caused notable increases in a number of TAGs that accumulated over the course of four days in the brains of DDHD2−/− mice [1].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: COS-7 cells. Tested Concentrations: 2μM. Incubation Duration: 16 hrs (hours). Experimental Results: Selective blocking of DDHD2 activity. |
| Animal Protocol |
Animal/Disease Models: Mouse[1].
Doses: 5-40 mg/kg. Management: IP, once. Experimental Results: No altered brain signatures were shown. |
| References |
|
| Molecular Formula |
C24H25F3N4O2
|
|---|---|
| Molecular Weight |
458.476115942001
|
| Exact Mass |
458.192
|
| Elemental Analysis |
C, 62.87; H, 5.50; F, 12.43; N, 12.22; O, 6.98
|
| CAS # |
1632236-44-2
|
| PubChem CID |
126970670
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
561.0±60.0 °C at 760 mmHg
|
| Flash Point |
293.1±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.591
|
| LogP |
5.87
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
615
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1=CC(C2=CC=C(OC(F)(F)F)C=C2)=NN1C(N(C1CCCCC1)CCC1=CC=CC=C1)=O
|
| InChi Key |
FYOYNRLSBYWAHL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H25F3N4O2/c25-24(26,27)33-21-13-11-19(12-14-21)22-17-28-31(29-22)23(32)30(20-9-5-2-6-10-20)16-15-18-7-3-1-4-8-18/h1,3-4,7-8,11-14,17,20H,2,5-6,9-10,15-16H2
|
| Chemical Name |
N-cyclohexyl-N-(2-phenylethyl)-4-[4-(trifluoromethoxy)phenyl]triazole-2-carboxamide
|
| Synonyms |
KLH45; KLH-45; KLH 45;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~180 mg/mL (~392.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.5 mg/mL (9.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.5 mg/mL (9.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 4.5 mg/mL (9.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1811 mL | 10.9056 mL | 21.8112 mL | |
| 5 mM | 0.4362 mL | 2.1811 mL | 4.3622 mL | |
| 10 mM | 0.2181 mL | 1.0906 mL | 2.1811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
